These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 32087148)

  • 1. The Amyloid Inhibitor CLR01 Relieves Autophagy and Ameliorates Neuropathology in a Severe Lysosomal Storage Disease.
    Monaco A; Maffia V; Sorrentino NC; Sambri I; Ezhova Y; Giuliano T; Cacace V; Nusco E; De Risi M; De Leonibus E; Schrader T; Klärner FG; Bitan G; Fraldi A
    Mol Ther; 2020 Apr; 28(4):1167-1176. PubMed ID: 32087148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Molecular Tweezer Ameliorates Motor Deficits in Mice Overexpressing α-Synuclein.
    Richter F; Subramaniam SR; Magen I; Lee P; Hayes J; Attar A; Zhu C; Franich NR; Bove N; De La Rosa K; Kwong J; Klärner FG; Schrader T; Chesselet MF; Bitan G
    Neurotherapeutics; 2017 Oct; 14(4):1107-1119. PubMed ID: 28585223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lysosomal dysfunction disrupts presynaptic maintenance and restoration of presynaptic function prevents neurodegeneration in lysosomal storage diseases.
    Sambri I; D'Alessio R; Ezhova Y; Giuliano T; Sorrentino NC; Cacace V; De Risi M; Cataldi M; Annunziato L; De Leonibus E; Fraldi A
    EMBO Mol Med; 2017 Jan; 9(1):112-132. PubMed ID: 27881461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The molecular tweezer CLR01 reduces aggregated, pathologic, and seeding-competent α-synuclein in experimental multiple system atrophy.
    Herrera-Vaquero M; Bouquio D; Kallab M; Biggs K; Nair G; Ochoa J; Heras-Garvin A; Heid C; Hadrovic I; Poewe W; Wenning GK; Klärner FG; Schrader T; Bitan G; Stefanova N
    Biochim Biophys Acta Mol Basis Dis; 2019 Nov; 1865(11):165513. PubMed ID: 31319154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The molecular tweezer CLR01 inhibits aberrant superoxide dismutase 1 (SOD1) self-assembly
    Malik R; Meng H; Wongkongkathep P; Corrales CI; Sepanj N; Atlasi RS; Klärner FG; Schrader T; Spencer MJ; Loo JA; Wiedau M; Bitan G
    J Biol Chem; 2019 Mar; 294(10):3501-3513. PubMed ID: 30602569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brain Targeting in MPS-IIIA.
    Sorrentino NC; Fraldi A
    Pediatr Endocrinol Rev; 2016 Jun; 13 Suppl 1():630-8. PubMed ID: 27491210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of Mutant αB Crystallin-Induced Protein Aggregation by a Molecular Tweezer.
    Xu N; Bitan G; Schrader T; Klärner FG; Osinska H; Robbins J
    J Am Heart Assoc; 2017 Aug; 6(8):. PubMed ID: 28862927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A block of autophagy in lysosomal storage disorders.
    Settembre C; Fraldi A; Jahreiss L; Spampanato C; Venturi C; Medina D; de Pablo R; Tacchetti C; Rubinsztein DC; Ballabio A
    Hum Mol Genet; 2008 Jan; 17(1):119-29. PubMed ID: 17913701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early disease course is unaltered in mucopolysaccharidosis type IIIA (MPS IIIA) mice lacking α-synuclein.
    Soe K; Beard H; Neumann D; Trim PJ; Duplock S; Snel MF; Hopwood JJ; Hemsley KM
    Neuropathol Appl Neurobiol; 2019 Dec; 45(7):715-731. PubMed ID: 30907009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluoxetine ameliorates mucopolysaccharidosis type IIIA.
    Capuozzo A; Montefusco S; Cacace V; Sofia M; Esposito A; Napolitano G; Nusco E; Polishchuk E; Pizzo MT; De Risi M; De Leonibus E; Sorrentino NC; Medina DL
    Mol Ther; 2022 Apr; 30(4):1432-1450. PubMed ID: 35121108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trehalose reduces retinal degeneration, neuroinflammation and storage burden caused by a lysosomal hydrolase deficiency.
    Lotfi P; Tse DY; Di Ronza A; Seymour ML; Martano G; Cooper JD; Pereira FA; Passafaro M; Wu SM; Sardiello M
    Autophagy; 2018; 14(8):1419-1434. PubMed ID: 29916295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disease pathogenesis explained by basic science: lysosomal storage diseases as autophagocytic disorders.
    Ballabio A
    Int J Clin Pharmacol Ther; 2009; 47 Suppl 1():S34-8. PubMed ID: 20040309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuronal-specific impairment of heparan sulfate degradation in Drosophila reveals pathogenic mechanisms for Mucopolysaccharidosis type IIIA.
    Webber DL; Choo A; Hewson LJ; Trim PJ; Snel MF; Hopwood JJ; Richards RI; Hemsley KM; O'Keefe LV
    Exp Neurol; 2018 May; 303():38-47. PubMed ID: 29408731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CLR01 protects dopaminergic neurons in vitro and in mouse models of Parkinson's disease.
    Bengoa-Vergniory N; Faggiani E; Ramos-Gonzalez P; Kirkiz E; Connor-Robson N; Brown LV; Siddique I; Li Z; Vingill S; Cioroch M; Cavaliere F; Threlfell S; Roberts B; Schrader T; Klärner FG; Cragg S; Dehay B; Bitan G; Matute C; Bezard E; Wade-Martins R
    Nat Commun; 2020 Sep; 11(1):4885. PubMed ID: 32985503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and pharmacological characterization of the molecular tweezer CLR01 - a broad-spectrum inhibitor of amyloid proteins' toxicity.
    Attar A; Chan WT; Klärner FG; Schrader T; Bitan G
    BMC Pharmacol Toxicol; 2014 Apr; 15():23. PubMed ID: 24735982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-amyloid treatment is broadly effective in neuronopathic mucopolysaccharidoses and synergizes with gene therapy in MPS-IIIA.
    Giaccio M; Monaco A; Galiano L; Parente A; Borzacchiello L; Rubino R; Klärner FG; Killa D; Perna C; Piccolo P; Marotta M; Pan X; Khijniak M; Siddique I; Schrader T; Pshezhetsky AV; Sorrentino NC; Bitan G; Fraldi A
    Mol Ther; 2024 Nov; 32(11):4108-4121. PubMed ID: 39342429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose, continuous enzyme replacement therapy ameliorates brain pathology in the neurodegenerative lysosomal disorder mucopolysaccharidosis type IIIA.
    King B; Hassiotis S; Rozaklis T; Beard H; Trim PJ; Snel MF; Hopwood JJ; Hemsley KM
    J Neurochem; 2016 May; 137(3):409-22. PubMed ID: 26762778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Supramolecular Mechanism of Viral Envelope Disruption by Molecular Tweezers.
    Weil T; Groß R; Röcker A; Bravo-Rodriguez K; Heid C; Sowislok A; Le MH; Erwin N; Dwivedi M; Bart SM; Bates P; Wettstein L; Müller JA; Harms M; Sparrer K; Ruiz-Blanco YB; Stürzel CM; von Einem J; Lippold S; Read C; Walther P; Hebel M; Kreppel F; Klärner FG; Bitan G; Ehrmann M; Weil T; Winter R; Schrader T; Shorter J; Sanchez-Garcia E; Münch J
    J Am Chem Soc; 2020 Oct; 142(40):17024-17038. PubMed ID: 32926779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic immune challenge exacerbates neurodegeneration in a model of neurological lysosomal disease.
    Mandolfo O; Parker H; Aguado È; Ishikawa Learmonth Y; Liao AY; O'Leary C; Ellison S; Forte G; Taylor J; Wood S; Searle R; Holley RJ; Boutin H; Bigger BW
    EMBO Mol Med; 2024 Jul; 16(7):1579-1602. PubMed ID: 38890537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of three amyloid assembly inhibitors: the sugar scyllo-inositol, the polyphenol epigallocatechin gallate, and the molecular tweezer CLR01.
    Sinha S; Du Z; Maiti P; Klärner FG; Schrader T; Wang C; Bitan G
    ACS Chem Neurosci; 2012 Jun; 3(6):451-8. PubMed ID: 22860214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.